Antidepressants, Anxiolytics, and Hair Loss: A Scalp Care Approach When You Can’t Stop the Medication2026.09.14
“My hair started falling out after I began taking antidepressants.” “I’ve been on anti-anxiety medication for years and my hair is thinning.” We often hear these concerns from patients currently under psychiatric or psychosomatic care. Because pharmacotherapy for depression and anxiety disorders is typically continued for months or years, the option of “just stop the drug and see if the shedding decreases” is often not realistic. In this article, our supervising physician discusses the mechanisms of antidepressant-induced hair loss and how to design a scalp treatment plan that runs in parallel with continued medication.
Key Points of This Article
・Antidepressant-induced hair loss centers on telogen effluvium caused by SSRIs, SNRIs, and tricyclics, and is often reversible
・Benzodiazepine anxiolytics rarely cause hair loss directly; instead they influence the hair cycle indirectly through insomnia and autonomic imbalance
・Stopping the medication independently carries serious psychiatric risk, so the classic “stop and confirm” diagnostic strategy is not realistic
・Scalp treatments using stem cell conditioned media have essentially no theoretical pharmacological interaction with antidepressants or anxiolytics, making them well suited for parallel use
・Effects should be evaluated over 3–6 month hair cycles, and information should be shared with the psychiatric attending physician throughout
Mechanisms of Antidepressant-Induced Hair Loss (Including Anxiolytics)
The core pathology of antidepressant-induced hair loss is “drug-induced telogen effluvium.” Hair follicles cycle through anagen, catagen, and telogen phases, but when medications affect metabolism, neurotransmission, or the autonomic nervous system, many follicles simultaneously shorten anagen and are pushed into telogen. Massive shedding then occurs 3–4 months later, and patients notice a clear increase in hair falling out during shampooing or found on the pillow.
Telogen Effluvium from SSRIs, SNRIs, and Tricyclics
Selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic/tetracyclic antidepressants are widely used in depression treatment. International drug-induced alopecia databases (such as the WHO VigiBase) list fluoxetine, paroxetine, sertraline, escitalopram, duloxetine, venlafaxine, and amitriptyline as suspect drugs for telogen effluvium. The frequency is not high, but onset 2–6 months after starting the drug is a typical timeline.
The Role of Benzodiazepine Anxiolytics
Benzodiazepines such as diazepam, alprazolam, etizolam, and lorazepam have scant evidence of directly acting on hair follicles to cause loss. However, chronic anxiety and insomnia are typically accompanied by elevated cortisol, sympathetic dominance, and reduced sleep quality — all factors that degrade the hair follicle stem cell niche. Rather than “the anxiolytic is causing hair loss,” the clinical picture is often better read as “the very state that requires an anxiolytic is straining the follicles.”
The Reality: “Stop the Drug to Confirm” Is Not an Option
The classic method for diagnosing drug-induced hair loss is a dechallenge/rechallenge test — briefly stopping the suspect medication to see whether shedding decreases. However, unilateral discontinuation of antidepressants or anxiolytics can cause psychiatric complications far more serious than hair loss, including relapse of depression, discontinuation syndrome, and self-harm risk. Reducing or stopping the drug on one’s own for the sake of hair issues must be absolutely avoided.
In clinical practice, we assess the possibility of antidepressant-induced hair loss indirectly — by matching the timeline of drug initiation with the increase in shedding, and carefully ruling out other causes such as thyroid dysfunction, low iron/ferritin, coexisting AGA/FAGA, and postpartum shedding. Since the gold-standard diagnostic method cannot be used, clinical judgment must be built from the accumulation of surrounding information. Supporting the scalp side without stopping the drug becomes the realistic landing point.
Designing Scalp Treatment That Runs Parallel to Ongoing Medication
The need to “keep the medication but stop the shedding” is answered by a parallel scalp treatment design. Working with the psychiatric attending physician and choosing treatments with essentially no theoretical pharmacological interaction with antidepressants or anxiolytics is important both for safety and for the patient’s peace of mind.
Stem Cell Conditioned Media as an Option
Stem cell conditioned media is a supernatant containing growth factors, cytokines, and exosomes secreted into the extracellular space when adipose-derived mesenchymal stem cells and similar cells are cultured. Delivered locally to the scalp, it is expected to shift follicles biased toward telogen back toward anagen. Because it is administered locally, systemic absorption is extremely limited, and it is unlikely to affect the central nervous system actions of SSRIs or benzodiazepines or the hepatic metabolic pathways (CYP enzymes) — a feature that is easy to explain to patients who must remain on psychiatric medication. For more information, please also see the hair regenerative medicine column list.
Treatment Frequency and Evaluation Timing
When antidepressant-induced hair loss is in the background, the typical design is treatment every 2–4 weeks during a 3–4 month induction phase to align with the hair cycle transition, followed by a maintenance phase every 8–12 weeks. Evaluations at 3 and 6 months using standardized photographs — combined where possible with tracking of psychiatric symptom scores such as PHQ-9 and GAD-7 — make it easier to share with the attending physician “how the drug’s efficacy and the hair’s response are moving together.” For guidelines on AGA and hair loss care, please refer to the Japanese Dermatological Association, and if AGA coexists, oral and topical indications should be considered in parallel.
Information to Share with Your Attending Physician Before Treatment
Information we would like you to bring on your first visit: (1) all currently prescribed psychiatric medications, doses, and start dates (a copy of your medication booklet is ideal), (2) the contact information or referral letter from your psychiatric/psychosomatic attending physician, (3) when your shedding clearly began to increase, (4) any past AGA treatments (oral, topical, or hair regenerative medicine) and, for women, menstrual/pregnancy/delivery history, and (5) blood test data from the past six months (ferritin, TSH, free T4, zinc, etc.). With these in hand, we can separate antidepressant-induced hair loss from other causes and design a safe scalp treatment plan that does not interfere with psychiatric care.
Frequently Asked Questions
Q. My shedding has surged four months after starting an SSRI. Should I reduce the drug immediately?
Please avoid reducing or stopping the drug on your own. Even when the timing of shedding coincides with SSRI initiation, it is not uncommon for other factors such as seasonal shedding, rapid weight changes, or iron deficiency to overlap. The safe and accurate order is to first report the “hair change” to your psychiatric attending physician, and then have a hair specialist carefully rule out other causes.
Q. I’ve been on anxiolytics (such as etizolam) for years. Is it safe to receive scalp treatment?
Scalp treatments using stem cell conditioned media are administered locally and have minimal systemic pharmacokinetic impact, so no pharmacological interactions with benzodiazepines have been reported at this time. However, if you experience strong anxiety or tension during procedures, consulting with your attending physician in advance about the use of a pro re nata dose will allow you to receive treatment more comfortably on the day.
Q. Will my hair return if I stop the antidepressant?
Drug-induced telogen effluvium is often reversible, and the hair cycle is generally reported to normalize within 3–6 months after discontinuation. However, if AGA or FAGA is in the background, that will continue to progress, so we often see cases in clinical practice where post-discontinuation recovery has “AGA-related shedding” layered on top. Please discuss the timing of any discontinuation with your attending physician.
Q. How should the psychiatric attending physician and the aesthetic clinic coordinate?
If you bring a copy of your medication booklet at your first visit, we can prepare a document for your attending physician summarizing the treatment content, medications used, and treatment frequency. This allows the psychiatric side to continuously monitor whether the scalp treatment is affecting mood or sleep, ensuring safety in both directions.
Q. My depression makes even attending appointments a burden. Is there a way to continue treatment without frequent visits?
During the induction phase, 1–2 visits per month is ideal, but flexible design that extends intervals based on your condition is possible. We will guide you on standardized home photography (same lighting, angle, and distance) so that the physician can objectively assess progress on your visit days.
──────────────
Supervising Physician: Shin Moriwaki / 森脇 進
Member of the Japan Society of Aesthetic Surgery (JSAS)
Member of the American Academy of Aesthetic Medicine
ECFMG Certificate
──────────────
📍AVAN TOKYO Ginza Hair Regenerative Medicine
English / 中文 / Tiếng Việt available
Inquiries welcome via DM / LINE / Website / Phone.